Cridanimod (Standard)

Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer[1][2].

Product Specifications

CAS Number

[38609-97-1]

UNSPSC

12352005

Target

IFNAR; Progesterone Receptor

Related Pathways

Immunology/Inflammation; Vitamin D Related/Nuclear Receptor

Field of Research

Inflammation/Immunology; Cancer

Smiles

O=C(O)CN(C1=C2C=CC=C1)C3=CC=CC=C3C2=O

Molecular Formula

C15H11NO3

Molecular Weight

253.26

References & Citations

[1]Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016|[2]Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.